Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Opportunity to Partner & Present

10:00 am - Thursday 1st October 2026

Please contact sponsor@hansonwade.com for more information.

Speakers:

Sydney Montesi

Clinical Investigator, Associate Professor of Medicine, Pulmonary

Massachusetts General Hospital and Harvard Medical School

Jeffrey Bornstein

Chief Medical Officer

Mediar Therapeutics

Camilla Graham

Vice President - Medical Affairs

PureTech Health

Opportunity to Partner & Present

Opportunity to Partner & Present

Speakers:

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By